One such new-generation long-acting insulin analog, insulin degludec (degludec), is a basal insulin with a duration of action exceeding 42 hours at steady state and a flat and stable glucose-lowering effect.11–13 The clinical benefits of degludec versus insulin detemir (IDet) in children and adolescents (1–17 years of age) with T1D were investigated in BEGIN YOUNG 1. This evidence concerns the gene INS and type 1 diabetes mellitus.